DP 4088

Drug Profile

DP 4088

Alternative Names: DP-4088; DPOC-4088

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Diakron Pharmaceuticals; Orchid Chemicals & Pharmaceuticals
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Blood coagulation disorders

Most Recent Events

  • 13 Apr 2016 This programme is still active
  • 23 Feb 2015 Diakron Pharmaceuticals terminates phase I trial in Healthy volunteers in Belgium (NCT01647620)
  • 01 Feb 2012 Diakron Pharmaceuticals initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT01647620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top